Rx Patent Cases For Five Drugs Could Lead To Delayed Generics - FDA

Five ongoing patent challenge cases have the potential to delay generic availability, FDA's Office of Generic Drugs Acting Director Gary Buehler told a House Commerce/Health Subcommittee hearing June 13.